Probiotix Health PLC Director/PDMR Shareholding
November 05 2024 - 9:33AM
RNS Regulatory News
RNS Number : 0492L
Probiotix Health PLC
05 November 2024
ProBiotix Health
plc
("ProBiotix" or the "Company" or, together with its
subsidiary, the "Group")
Director/PDMR
Shareholding
ProBiotix Health plc (AQSE: PBX),
the life sciences business developing probiotics to support
cardiometabolic health, is pleased to announce that Mark
Collingbourne, PBX's Company Secretary, has acquired 80,000
ordinary shares in the Company. Following this acquisition, Mr.
Collingbourne is interested in 91,093 ordinary shares in the
Company.
Further information about this
acquisition is set out in the table below.
For
further information, please contact:
|
ProBiotix Health plc
|
https://probiotixhealth-ir.com
|
|
Steen Andersen, Chief Executive
Officer
|
Contact via Walbrook
below
|
|
|
|
|
Peterhouse Capital Limited
(Aquis Corporate Adviser and
Broker)
|
|
|
Mark Anwyl
|
Tel: 020
7220 9793
|
|
|
|
|
Walbrook PR Ltd
|
probiotix@walbrookpr.com
|
|
Anna Dunphy
|
Mob: 07876
741 001
|
|
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with
them.
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Mark Collingbourne
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Company Secretary
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer, or auction monitor
|
|
a)
|
Name
|
ProBiotix Health plc
|
|
b)
|
LEI
|
98450048683CF0388C30
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
ordinary shares of 0.05p
each
ISIN: GB00BLNBFR86
|
|
b)
|
Nature of the transaction
|
Acquisition of ordinary
shares
|
|
c)
|
Price(s) and volume(s)
|
80,000 ordinary shares @ 5.5p per
share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
1 November 2024
|
|
f)
|
Place of the transaction
|
Aquis Growth Market
|
This announcement contains
information which, prior to its disclosure, was considered inside
information for the purposes of the UK Market Abuse Regulation and
the Directors of the Company are responsible for the release of
this announcement.
If you would like to keep up to date
with commercial news, please follow ProBiotix
Health on LinkedIn
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NEXBUBDBIDGDGSU
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Dec 2023 to Dec 2024
